Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

81. Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers

Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers 30062102 2018 11 14 2374-4677 4 2018 NPJ breast cancer NPJ Breast Cancer Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers. 19 10.1038/s41523-018-0070-x Breast cancer is an increasing problem in Asia, with a higher proportion of premenopausal patients who are at higher risk of recurrence. Targeted sequencing was performed on DNA extracted from (...) primary tumor specimens of 63 premenopausal Asian patients who relapsed after initial diagnosis of non-metastatic breast cancer. The most prevalent alterations included: TP53 (65%); PIK3CA (32%); GATA3 (29%); ERBB2 (27%); MYC (25%); KMT2C (21%); MCL1 (17%); PRKDC, TPR, BRIP1 (14%); MDM4, PCDH15, PRKAR1A, CDKN1B (13%); CCND1, KMT2D, STK11 , and MLH1 (11%). Sixty of the 63 patients (95%) had at least one genetic alteration in a signaling pathway related to cell cycle or p53 signaling. The presence

NPJ breast cancer2018 Full Text: Link to full Text with Trip Pro

82. Breast Cancer Stem Cells

Breast Cancer Stem Cells 30018256 2018 11 14 2227-9059 6 3 2018 Jul 17 Biomedicines Biomedicines Breast Cancer Stem Cells. E77 10.3390/biomedicines6030077 Breast cancer stem cells (BCSC) have been implicated in tumor initiation, progression, metastasis, recurrence, and resistance to therapy. The origins of BCSCs remain controversial due to tumor heterogeneity and the presence of such small side populations for study, but nonetheless, cell surface markers and their correlation with BCSC (...) . Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA. lmiele@lsuhsc.edu. eng Journal Article Review 2018 07 17 Switzerland Biomedicines 101691304 2227-9059 Hedgehog Hippo Notch Wnt breast cancer stem cells 2018 06 26 2018 07 13 2018 07 14 2018 7 19 6 0 2018 7 19 6 0 2018 7 19 6 1 epublish 30018256 biomedicines6030077 10.3390/biomedicines6030077 PMC6163894 Mol Med Rep. 2016 Dec;14(6):5261-5270 27779682 Nature. 2015 Feb 19;518(7539):422-6 25470049 Oncogene

Biomedicines2018 Full Text: Link to full Text with Trip Pro

83. Patient advocate involvement in the design and conduct of breast cancer clinical trials requiring the collection of multiple biopsies

Patient advocate involvement in the design and conduct of breast cancer clinical trials requiring the collection of multiple biopsies 30026963 2018 11 14 2056-7529 4 2018 Research involvement and engagement Res Involv Engagem Patient advocate involvement in the design and conduct of breast cancer clinical trials requiring the collection of multiple biopsies. 22 10.1186/s40900-018-0108-0 Breast cancer is a diverse and varied disease. Recent research has shown that the collection of multiple (...) biopsies before surgery can help researchers determine how the cancer is responding to treatment and can predict for long-term outcomes. However biopsies can be uncomfortable, and sometimes clinicians and research teams in hospitals may be reluctant to offer clinical trials requiring several biopsies to patients who have been recently diagnosed with breast cancer. The Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU) oversees a large number of breast cancer clinical trials

Research involvement and engagement2018 Full Text: Link to full Text with Trip Pro

84. Risks of ovarian, breast, and corpus uteri cancer in women treated with assisted reproductive technology in Great Britain, 1991-2010: data linkage study including 2.2 million person years of observation.

Risks of ovarian, breast, and corpus uteri cancer in women treated with assisted reproductive technology in Great Britain, 1991-2010: data linkage study including 2.2 million person years of observation. OBJECTIVE: To investigate the risks of ovarian, breast, and corpus uteri cancer in women who have had assisted reproduction. DESIGN: Large, population based, data linkage cohort study. SETTING AND PARTICIPANTS: All women who had assisted reproduction in Great Britain, 1991-2010, as recorded (...) by the Human Fertilisation and Embryology Authority (HFEA). INTERVENTIONS: HFEA fertility records for cohort members were linked to national cancer registrations. MAIN OUTCOME MEASURES: Observed first diagnosis of ovarian, breast, and corpus uteri cancer in cohort members were compared with age, sex, and period specific expectation. Standardised incidence ratios (SIRs) were calculated by use of age, sex, and period specific national incidence rates. RESULTS: 255 786 women contributed 2 257 789 person years

BMJ2018 Full Text: Link to full Text with Trip Pro

85. Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial.

Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial. Importance: Musculoskeletal symptoms are the most common adverse effects of aromatase inhibitors and often result in therapy discontinuation. Small studies suggest that acupuncture may decrease aromatase inhibitor-related joint symptoms. Objective: To determine the effect of acupuncture in reducing aromatase (...) inhibitor-related joint pain. Design, Setting, and Patients: Randomized clinical trial conducted at 11 academic centers and clinical sites in the United States from March 2012 to February 2017 (final date of follow-up, September 5, 2017). Eligible patients were postmenopausal women with early-stage breast cancer who were taking an aromatase inhibitor and scored at least 3 on the Brief Pain Inventory Worst Pain (BPI-WP) item (score range, 0-10; higher scores indicate greater pain). Interventions

JAMA2018

86. Progress in targeted therapy for breast cancer

Progress in targeted therapy for breast cancer 30276363 2018 11 14 2589-0514 4 3 2018 Sep Chronic diseases and translational medicine Chronic Dis Transl Med Progress in targeted therapy for breast cancer. 164-175 10.1016/j.cdtm.2018.04.002 Breast cancer is a multistep, multifactorial, and heterogeneous disease. Significant transformations have occurred in the systemic management of breast cancer in the past decade. Due to the further understanding of pathogenesis, scientists have found plenty (...) of signaling pathways and correspondingly therapeutic targets in breast cancer, such as hormone receptor, human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), phosphoinositide-3-kinase (PI3K), v-akt murine thymoma viral oncogene homolog (AKT), mechanistic target of rapamycin (mTOR), cyclin-dependent kinase 4/6 (CDK4/6), poly (adenosine diphosphate-ribose) polymerase (PARP), and programmed death-1 (PD-1). Targeted therapy, which

Chronic diseases and translational medicine2018 Full Text: Link to full Text with Trip Pro

87. Author Correction: Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study

Author Correction: Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study 30003141 2018 07 13 2374-4677 4 2018 NPJ breast cancer NPJ Breast Cancer Erratum: Author Correction: Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. 17 10.1038/s41523-018-0069-3 [This corrects the article DOI: 10.1038/npjbcancer.2016.17.]. Petkov Valentina I VI 1National Cancer Institute, Bethesda, MD (...) , Albuquerque, NM USA. 0000 0001 2188 8502 grid.266832.b Wu Xiao-Cheng XC 20Louisiana State University Health Sciences Center, New Orleans, LA USA. 0000 0000 8954 1233 grid.279863.1 Penberthy Lynne L 1National Cancer Institute, Bethesda, MD USA. 0000 0004 1936 8075 grid.48336.3a Shak Steven S 2Genomic Health, Inc., Redwood City, CA USA. 0000 0004 0458 1279 grid.467415.5 eng Published Erratum 2018 07 06 United States NPJ Breast Cancer 101674891 2374-4677 NPJ Breast Cancer. 2016 Jun 08;2:16017 28721379 2018 7

NPJ breast cancer2018 Full Text: Link to full Text with Trip Pro

88. Knowledge of Genetic Counseling Among Patients With Breast Cancer and Their Relatives at a Nigerian Teaching Hospital

Knowledge of Genetic Counseling Among Patients With Breast Cancer and Their Relatives at a Nigerian Teaching Hospital 30084716 2018 12 07 2378-9506 4 2018 Jul Journal of global oncology J Glob Oncol Knowledge of Genetic Counseling Among Patients With Breast Cancer and Their Relatives at a Nigerian Teaching Hospital. 1-8 10.1200/JGO.17.00158 Breast cancer prevalence continues to increase globally, and a significant proportion of the disease has been linked to genetic susceptibility. As we enter (...) the era of precision medicine, genetics knowledge and skills are increasingly essential for achieving optimal cancer prevention and care. However, in Nigeria, patients with breast cancer and their relatives are less knowledgeable about genetic susceptibility to chronic diseases. This pilot study collected qualitative data during in-depth interviews with 21 participants. Of these, 19 participants were patients with breast cancer and two were relatives of patients with breast cancer. Participants were

Journal of global oncology2018 Full Text: Link to full Text with Trip Pro

89. Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer

Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer 29978035 2018 11 14 2374-4677 4 2018 NPJ breast cancer NPJ Breast Cancer Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer. 16 10.1038/s41523-018-0066-6 The first genomic scar-based homologous recombination deficiency (HRD) measures were produced using SNP arrays. As array-based technology has (...) on the actual HRD measure) and that the NGS-based HRD scores distinguish similarly well between BRCA mutant and BRCA wild-type cases in a cohort of triple-negative breast cancer patients of the TCGA data set. Sztupinszki Zsofia Z 1Department of Bio and Health Informatics, Technical University of Denmark, Kemitorvet 208, Lyngby, 2800 Denmark. 0000 0001 2181 8870 grid.5170.3 Diossy Miklos M 1Department of Bio and Health Informatics, Technical University of Denmark, Kemitorvet 208, Lyngby, 2800 Denmark. 0000

NPJ breast cancer2018 Full Text: Link to full Text with Trip Pro

90. Symptoms Experience and Quality of Life in The Patients With Breast Cancer Receiving The Taxane Class of Drugs

Symptoms Experience and Quality of Life in The Patients With Breast Cancer Receiving The Taxane Class of Drugs 30123880 2018 11 14 14 3 2018 Jul European journal of breast health Eur J Breast Health Symptoms Experience and Quality of Life in The Patients With Breast Cancer Receiving The Taxane Class of Drugs. 148-155 10.5152/ejbh.2018.3785 The aim of this study is to evaluate the symptoms experience and quality of life in patients with breast cancer receiving the taxane class of drugs (...) . This study was performed between November 2015 March 2016 in a chemotherapy unit of a university hospital with 48 patients, who agreed to participate in the study. The Memorial Symptom Rating Score (MSAS), Socio-demographic and Clinical Features Form, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Breast (EORTC QLQ- BR23) measures specific to breast cancer

European journal of breast health2018 Full Text: Link to full Text with Trip Pro

91. Use of Alternative Medicine Is Delaying Health-Seeking Behavior by Bangladeshi Breast Cancer Patients

Use of Alternative Medicine Is Delaying Health-Seeking Behavior by Bangladeshi Breast Cancer Patients 30123883 2018 11 14 14 3 2018 Jul European journal of breast health Eur J Breast Health Use of Alternative Medicine Is Delaying Health-Seeking Behavior by Bangladeshi Breast Cancer Patients. 166-172 10.5152/ejbh.2018.3929 Various treatment options including alternative medicine is available in underdeveloped countries which attracts easily the community with low profile. This study aimed (...) to find perception of the use and mode use of alternative medicine (AM) by Bangladeshi Breast cancer patients which may influence timely treatment seeking. A cross sectional study was performed to determine the spectrum in use of alternative medicine and compare the use of alternative medicine with their delay in presentation. Patients were selected randomly from July 2015-June 2016 in a specialized public cancer hospital of Dhaka city. Face to face interview was taken from diagnosed breast cancer

European journal of breast health2018 Full Text: Link to full Text with Trip Pro

92. Favorable Long-Term Outcome in Male Breast Cancer

Favorable Long-Term Outcome in Male Breast Cancer 30123885 2018 11 14 14 3 2018 Jul European journal of breast health Eur J Breast Health Favorable Long-Term Outcome in Male Breast Cancer. 180-185 10.5152/ejbh.2018.3946 Male breast cancer (MBC) is a rare type of cancer in the breast cancer series and in the male population. Data is usually extrapolated from female breast cancer (FBC) studies. We aim to study the clinicopathological characteristics and outcome of MBC patients at our institution (...) and we aim to emphasize the differences compared with FBC. Between January 1993 and April 2016, 56 male patients who were diagnosed as breast cancer and underwent surgical operation were retrospectively analyzed. Patients were evaluated for demographical characteristics, surgery type, clinicopathological characteristics, adjuvant and neoadjuvant treatments, follow-up time, overall survival (OS), disease free survival (DFS), and disease specific survival (DSS). The ratio of MBC among all breast

European journal of breast health2018 Full Text: Link to full Text with Trip Pro

93. The Association of Health Literacy with Breast Cancer Knowledge, Perception and Screening Behavior

The Association of Health Literacy with Breast Cancer Knowledge, Perception and Screening Behavior 30123879 2018 11 14 14 3 2018 Jul European journal of breast health Eur J Breast Health The Association of Health Literacy with Breast Cancer Knowledge, Perception and Screening Behavior. 144-147 10.5152/ejbh.2018.3757 The incidence of breast cancer among Iranian women is increasing, and 70% of patients are diagnosed at advanced stages. The current study aimed at evaluating the association (...) of health literacy (HL) with breast cancer knowledge, perception, and screening behavior in women. The current cross- sectional, descriptive study was conducted on 250 women who referred to health centers in Zahedan, Iran. Data collection instrument included a demographic information form, Iranian Health Literacy Questionnaire (IHLQ), and Champion's health belief model scale. The majority of participants (89.6%) had limited HL. Participants with limited HL had less breast cancer knowledge, and less

European journal of breast health2018 Full Text: Link to full Text with Trip Pro

94. Why and How Should We Improve Breast Cancer Management in Elderly Women?

Why and How Should We Improve Breast Cancer Management in Elderly Women? 30123876 2018 11 14 14 3 2018 Jul European journal of breast health Eur J Breast Health Why and How Should We Improve Breast Cancer Management in Elderly Women? 132-133 10.5152/ejbh.2018.02070 Lodi Massimo M 0000-0002-7593-6378 Unit of Breast, Strasbourg University Hospital, Strasbourg, France. Department of Functional Genomics and Cancer, Institute of Genetics and of Molecular and Cellular Biology, Illkirch, France. Lodi (...) and Cellular Biology, Illkirch, France. Mathelin Carole C 0000-0002-7680-0210 Unit of Breast, Strasbourg University Hospital, Strasbourg, France. Department of Functional Genomics and Cancer, Institute of Genetics and of Molecular and Cellular Biology, Illkirch, France. Sarrebourg General Hospital, Sarrebourg, France. eng Editorial 2018 07 01 Turkey Eur J Breast Health 101709357 Conflict of Interest: The authors have no conflicts of interest to declare. 2018 04 22 2018 05 25 2018 8 21 6 0 2018 8 21 6 0

European journal of breast health2018 Full Text: Link to full Text with Trip Pro

95. Positive Axilla in Breast Cancer; Clinical Practice in 2018

Positive Axilla in Breast Cancer; Clinical Practice in 2018 30123877 2018 11 14 14 3 2018 Jul European journal of breast health Eur J Breast Health Positive Axilla in Breast Cancer; Clinical Practice in 2018. 134-135 10.5152/ejbh.2018.4132 Işık Arda A 0000-0001-9493-4055 Breast Surgery Unit, Department of Surgical Oncology, University of Pittsburgh Medical Center Magee-Womens Hospital, Pittsburgh, USA. Grassi Arial A Breast Surgery Unit, Department of Surgical Oncology, University of Pittsburgh (...) Medical Center Magee-Womens Hospital, Pittsburgh, USA. Soran Atilla A Breast Surgery Unit, Department of Surgical Oncology, University of Pittsburgh Medical Center Magee-Womens Hospital, Pittsburgh, USA. eng Editorial 2018 07 01 Turkey Eur J Breast Health 101709357 Conflict of Interest: No conflict of interest was declared by the authors. 2018 04 02 2018 04 05 2018 8 21 6 0 2018 8 21 6 0 2018 8 21 6 1 epublish 30123877 10.5152/ejbh.2018.4132 ejbh-14-3-134 PMC6092157 JAMA. 2017 Sep 12;318(10):918-926

European journal of breast health2018 Full Text: Link to full Text with Trip Pro

96. Immunohistochemical HER2 Status Evaluation in Breast Cancer Pathology Samples: A Multicenter, Parallel-Design Concordance Study

Immunohistochemical HER2 Status Evaluation in Breast Cancer Pathology Samples: A Multicenter, Parallel-Design Concordance Study 30123882 2018 11 14 14 3 2018 Jul European journal of breast health Eur J Breast Health Immunohistochemical HER2 Status Evaluation in Breast Cancer Pathology Samples: A Multicenter, Parallel-Design Concordance Study. 160-165 10.5152/ejbh.2018.3961 As patients with increased human epidermal growth factor receptor (HER2) overexpression are more likely to benefit from (...) trastuzumab treatment, the accuracy of HER2 receptor status in breast cancer patients is significant for appropriate disease management. However, this assessment is not harmonized and results may be highly variable between centers. The aim of this study was to investigate the degree of interlaboratory variability in the results of HER2 expression reported by 5 participating centers and to assess the concordance between these centers and a reference laboratory. Materials and Methods : A total of 30 breast

European journal of breast health2018 Full Text: Link to full Text with Trip Pro

97. Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5

Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5 29676944 2018 06 27 1527-7755 36 19 2018 Jul 01 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 (...) Years of Endocrine Therapy: CTS5. 1941-1948 10.1200/JCO.2017.76.4258 Purpose Estimating risk of late distant recurrence (DR) is an important goal for managing women with hormone receptor-positive breast cancer after 5 years of endocrine treatment without recurrence. We developed and validated a simple clinicopathologic tool (Clinical Treatment Score post-5 years [CTS5]) to estimate residual risk of DR after 5 years of endocrine treatment. Patients and Methods The ATAC (Arimidex, Tamoxifen, Alone

EvidenceUpdates2018

98. Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE

Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE 29664714 2018 05 29 1527-7755 36 16 2018 Jun 01 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal (...) Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102. 1556-1563 10.1200/JCO.2017.76.9331 Purpose The mammalian target of rapamycin inhibitor everolimus targets aberrant signaling through the PI3K/AKT/mammalian target of rapamycin pathway, a mechanism of resistance to anti-estrogen therapy in estrogen receptor (ER)-positive breast cancer. We hypothesized that everolimus plus

EvidenceUpdates2018

99. Reducing Body Image-Related Distress in Women With Breast Cancer Using a Structured Online Writing Exercise: Results From the My Changed Body Randomized Controlled Trial

Reducing Body Image-Related Distress in Women With Breast Cancer Using a Structured Online Writing Exercise: Results From the My Changed Body Randomized Controlled Trial 29688834 2018 06 27 1527-7755 36 19 2018 Jul 01 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Reducing Body Image-Related Distress in Women With Breast Cancer Using a Structured Online Writing Exercise: Results From the My Changed Body Randomized Controlled Trial (...) . 1930-1940 10.1200/JCO.2017.76.3318 Purpose Breast cancer treatment adverse effects result in one in three survivors experiencing body image-related distress (BID) that negatively impacts on a woman's ability to recover after cancer and into survivorship. My Changed Body (MyCB) is a Web-based psychological intervention to alleviate BID and improve body appreciation in survivors of breast cancer (BCSs) through a single-session, self-compassion focused writing activity. This randomized controlled

EvidenceUpdates2018

100. Model for Predicting Breast Cancer Risk in Women With Atypical Hyperplasia

Model for Predicting Breast Cancer Risk in Women With Atypical Hyperplasia 29676945 2018 06 28 1527-7755 36 18 2018 Jun 20 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Model for Predicting Breast Cancer Risk in Women With Atypical Hyperplasia. 1840-1846 10.1200/JCO.2017.75.9480 Purpose Women with atypical hyperplasia (AH) on breast biopsy have an aggregate increased risk of breast cancer (BC), but existing risk prediction models do (...) United States Journal Article 2018 04 20 United States J Clin Oncol 8309333 0732-183X Am J Epidemiol. 1988 Sep;128(3):467-77 3414655 J Natl Cancer Inst. 2017 Oct 1;109 (10 ): 28376198 J Natl Cancer Inst. 2005 Nov 16;97(22):1652-62 16288118 N Engl J Med. 1985 Jan 17;312(3):146-51 3965932 Breast Cancer Res Treat. 2015 Aug;152(3):687-94 26202055 N Engl J Med. 2011 Jun 23;364(25):2381-91 21639806 J Mammary Gland Biol Neoplasia. 2007 Mar;12(1):71-82 17318269 Breast Cancer Res Treat. 2017 Sep;165(2):285

EvidenceUpdates2018